NCT05161195 2026-02-02
Roll-over Study to Allow Continued Access to Ribociclib
Novartis
Phase 4 Active not recruiting
Novartis
Ottawa Hospital Research Institute
Palleos Healthcare GmbH
Fred Hutchinson Cancer Center
Institut Claudius Regaud
Institut Claudius Regaud
Peking Union Medical College Hospital
Institut Claudius Regaud
AstraZeneca
AstraZeneca
AstraZeneca
AstraZeneca